256 related articles for article (PubMed ID: 11007055)
1. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
[TBL] [Abstract][Full Text] [Related]
3. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
Niitsu N; Umeda M
Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
[TBL] [Abstract][Full Text] [Related]
4. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
5. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
8. Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.
Okabe M; Maekawa I; Suzuki S; Higuchi M; Morioka M; Nishi K; Itaya T; Ohmura T; Kawamura M; Fuzimoto N
Leuk Lymphoma; 1995 Nov; 19(5-6):485-91. PubMed ID: 8590851
[TBL] [Abstract][Full Text] [Related]
9. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Niitsu N; Umeda M
Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
[TBL] [Abstract][Full Text] [Related]
10. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study.
Niitsu N; Iijima K
Ann Hematol; 2001 Oct; 80(10):602-6. PubMed ID: 11732872
[TBL] [Abstract][Full Text] [Related]
11. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Kohori M; Aoki S; Miura I; Hirano M
Hematol Oncol; 2006 Dec; 24(4):220-6. PubMed ID: 16958147
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
15. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
16. A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Burton C; Linch D; Hoskin P; Milligan D; Dyer MJ; Hancock B; Mouncey P; Smith P; Qian W; MacLennan K; Jack A; Webb A; Cunningham D
Br J Cancer; 2006 Mar; 94(6):806-13. PubMed ID: 16508640
[TBL] [Abstract][Full Text] [Related]
17. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
[TBL] [Abstract][Full Text] [Related]
18. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
Sweetenham JW; Mead GM; Whitehouse JM
J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
[TBL] [Abstract][Full Text] [Related]
19. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
20. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]